Conversion to LCP Tacrolimus Mitigates Calcineurin‐Induced Nephrotoxicity in Patients After Liver Transplantation
Clinical Transplantation · 2026-06 · 40 (6)
DOI: 10.1111/ctr.70602 ↗At a glance
Journal article in Clinical Transplantation, published online on 2026-06-23. Written by Maximilian Joseph Brol and 15 co-authors. Institution: Department of Internal Medicine B, University Hospital Münster, Münster, Germany. Major MEDLINE topics: Tacrolimus, Liver Transplantation, Calcineurin Inhibitors, Graft Rejection. 27 references. The full text is freely available (open access, CC BY 4.0). Funded by: Deutsche Forschungsgemeinschaft, Horizon 2020 Framework Programme, Eurostars.
Abstract (original language)
Background
Calcineurin inhibitor (CNI)‐induced nephrotoxicity after liver transplantation (LT) is linked to increased morbidity and mortality. LCPT offers a particular extended‐release formulation, potentially improving the concentration‐dose (C/D) ratio and renal outcomes. This study investigated the impact of switching from standard‐release Tacrolimus (SR‐Tac) to LCPT on C/D ratio and renal function.
Methods
170 adult LT recipients (August 2008–March 2020) treated with tacrolimus for at least two years were included. In this single‐center, retrospective analysis, 63 patients converted to LCPT, while 107 patients continued on SR‐Tac. Clinical data were collected every three months over 24 months.
Results
At baseline, median C/D ratios were similar between groups ( p = 0.553), the LCPT group showed significantly higher C/D ratios compared to SR‐Tac during both the first ( p = 0.003) and second year ( p = 0.004). While LCPT‐treated patients showed an increased mean estimated glomerular filtration rate (eGFR), the SR‐Tac group exhibited a progressive decline at each follow‐up (mean decline: −5.4 mL/min/1.73m 2 at 24 months, p
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Internal Medicine B, University Hospital Münster, Münster, Germany.
- Department of General, Visceral and Transplant Surgery, University Hospital Münster, Münster, Germany.
- Department of Hepatology, Gastroenterology and Transplantation Medicine, University Hospital Essen, Essen, Germany.
- European Foundation for the Study of Chronic Liver Failure-EF Clif, Barcelona, Spain.
ORCID profiles: Maximilian Joseph Brol, Iyad Kabar, Philipp Stephan Althaus, Wenyi Gu, Frank Erhard Uschner, Michael Praktiknjo, Kai-Henrik Peiffer, Philipp Houben, Andreas Pascher, Hartmut H Schmidt, Jonel Trebicka
Funding
- Deutsche Forschungsgemeinschaft
- Horizon 2020 Framework Programme
- Eurostars
- Hessisches Ministerium für Wissenschaft und Kunst
- Bundesministerium für Bildung und Forschung
Cite
APA
Brol, M. J., Munske, I., Kabar, I., Althaus, P. S., Gu, W., Uschner, F. E., Praktiknjo, M., McCoy, M. S., Peiffer, K. H., Rennebaum, F., Houben, P., Pascher, A., Schmidt, H. H., Trebicka, J., Schomacher, T., & Hüsing-Kabar, A. (2026). Conversion to LCP Tacrolimus Mitigates Calcineurin‐Induced Nephrotoxicity in Patients After Liver Transplantation. Clinical Transplantation, 40(6). https://doi.org/10.1111/ctr.70602
Vancouver
Brol MJ, Munske I, Kabar I, Althaus PS, Gu W, Uschner FE, et al. Conversion to LCP Tacrolimus Mitigates Calcineurin‐Induced Nephrotoxicity in Patients After Liver Transplantation. Clinical Transplantation. 2026;40(6). doi:10.1111/ctr.70602
BibTeX
@article{Brol2026,
author = {Brol, Maximilian Joseph and Munske, Isabella and Kabar, Iyad and Althaus, Philipp Stephan and Gu, Wenyi and Uschner, Frank Erhard and Praktiknjo, Michael and McCoy, Martin Sebastian and Peiffer, Kai-Henrik and Rennebaum, Florian and Houben, Philipp and Pascher, Andreas and Schmidt, Hartmut H and Trebicka, Jonel and Schomacher, Tina and Hüsing-Kabar, Anna},
title = {Conversion to LCP Tacrolimus Mitigates Calcineurin‐Induced Nephrotoxicity in Patients After Liver Transplantation},
journal = {Clinical Transplantation},
year = {2026},
volume = {40},
number = {6},
doi = {10.1111/ctr.70602}
}
EUVIMED